StockWatch: Antitrust Fears Dampen Support for $43B Pfizer-Seagen Deal

Pfizer's planned $43 billion purchase of Seagen didn't spark the usual huge stock surge, due to antitrust review concerns.

Related Keywords

,David Risinger ,Jay Olson ,Gregory Renza ,Raymond James ,Albert Bourla ,Zhiqiang Shu ,Gena Wang ,Etzer Darout ,Reni Benjamin ,Dane Leone ,Andrew Berens ,David Epstein ,Biotech Equity Research ,Merck Co ,Reuters ,Pfizer ,Merck Kga ,European Union ,Allergan ,Merck Kgaa ,Us Federal Trade Commission ,Bristol Myers Squibb ,Barclays ,Trade Commission ,Senior Managing Director ,Targeted Oncology ,Managing Director ,Senior Analyst ,Market Perform ,Berenberg Capital Markets ,